Close

News

POA Pharma GmbH announces Germany’s Medical Nutrition Scholarship Winners for 2023

01 Nov 2023

POA Pharma GmbH, a speciality pharmaceutical company based in Sprockhövel, has announced the winners of its Medical Nutrition Scholarship Award for 2023 as Emilie Göllner and Kim Hamberger.

The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such as Phenylketonuria (PKU) and Tyrosinemia (TYR), [...]

Read more
POA Pharma GmbH announces Germany’s Medical Nutrition Scholarship Winners for 2023
POA Pharma announces the launch of PKU Easy Microtabs Plus into the European Market

POA Pharma announces the launch of PKU Easy Microtabs Plus into the European Market

11 Oct 2023

POA Pharma, the privately-owned pharmaceutical sales and marketing company, has today announced the launch of PKU Easy Microtabs Plus in Germany and the Nordic region.

PKU Easy Microtabs Plus, which are specifically for individuals with Phenylketonuria (PKU), mark POA Pharma GmbH’s entry into the inborn metabolic disease (IMD) market.

The new PKU EASY Microtabs...

Read more

POA Pharma announces launch of activities in Germany

20 Apr 2023

POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced its expansion into Germany as POA Pharma GmbH.

POA Pharma, headquartered in Copenhagen with additional facilities located across the Nordic region, is part of Galen Limited.  This privately owned company, which was established in 1968, has global headquarters [...]

Read more
POA Pharma announces launch of activities in Germany
POA Pharma, enters the German market, securing exclusive in-licensing rights for Rapilose Oral Glucose Solution (OGS)

POA Pharma, enters the German market, securing exclusive in-licensing rights for Rapilose Oral Glucose Solution (OGS)

19 Sep 2022

POA Pharma Scandinavia AB, a Galen Limited owned company, has announced its entry into the German market, securing an exclusive in-licensing agreement with Penlan Healthcare Limited for Rapilose OGS.

POA Pharma’s parent company, Galen Limited, a global pharmaceutical company, and proud member of the Almac Group, has an existing, long standing in-licensing relationship with Penlan...

Read more

Galen Medical Nutrition Announces Scholarship Award is open for applications

26 Jul 2021

Supporting patients with metabolic disorders accessing further education

Craigavon, U.K. – 27 Jul 2021 - Galen, the privately-owned pharmaceutical sales and marketing company, is pleased to announce the inaugural Galen Medical Nutrition Scholarship Award designed to support people with metabolic disorders, such as Phenylketonuria (PKU), accessing further education, training and development courses or apprenticeships.

Entrants [...]

Read more
Galen Medical Nutrition Announces Scholarship Award is open for applications
Galen Announces Completion of Multi-Million Pound POA Pharma Acquisition

Galen Announces Completion of Multi-Million Pound POA Pharma Acquisition

07 Jan 2020

Move adds substantial new therapeutic areas and territories to Galen’s reach

Craigavon, N.I., 8 Jan 2020 - Galen, the privately owned global pharmaceutical sales and marketing company, today announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global reach and...

Read more

You are about to leave this website to go to an external website.

POA Pharma does not take any responsibility for content hosted on external websites.

Click to proceed
By using this website, you agree to the terms of the site and use of cookies as described in our Privacy Policy.